Albert White III
About Albert White III
Albert G. White III (age 55) joined the Evolus board on July 1, 2024 and is standing for election as a Class I director through 2028. He is President & CEO and a director of The Cooper Companies, Inc. (NASDAQ: COO), previously serving as CFO, EVP & Chief Strategy Officer; earlier roles include Director at KeyBanc Capital Markets and leadership positions at KeyBank. He holds an MBA and B.S. in Finance from Virginia Tech. He is deemed independent under Nasdaq rules.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| The Cooper Companies, Inc. | President & CEO; Director | May 2018–present | Led a global medtech portfolio spanning contact lenses, fertility and women’s health |
| The Cooper Companies, Inc. | CFO | Nov 2016–May 2018 | Oversight of finance and public-company reporting |
| The Cooper Companies, Inc. | EVP & Chief Strategy Officer | Dec 2015–Nov 2016 | Corporate strategy, M&A, portfolio planning |
| Cooper Medical Inc. (parent of CooperSurgical) | CEO | Aug 2015–May 2018 | Directed women’s healthcare business |
| The Cooper Companies, Inc. | VP Investor Relations | Nov 2007–Mar 2013 | Capital markets communications |
| The Cooper Companies, Inc. | VP & Treasurer | Apr 2006–Dec 2012 | Treasury, liquidity management |
| KeyBanc Capital Markets / KeyBank | Director; multiple leadership roles | ~1998–2006 | Banking, capital markets experience |
External Roles
| Organization | Role | Public Company? | Committees/Notes |
|---|---|---|---|
| The Cooper Companies, Inc. (COO) | Director; President & CEO | Yes | Current directorship; senior executive |
Board Governance
- Independence: The board determined White is independent under Nasdaq rules; independent directors comprise a majority of the board and all standing committees.
- Committee assignments: Compensation Committee member; initially appointed to the Regulatory & Compliance Committee upon joining the board (current proxy does not list this committee among standing committees). Not a committee chair.
- Attendance and engagement: Board held six meetings in 2024; each director attended at least 75% of board and committee meetings; non‑employee directors hold executive sessions during regular meetings.
- Board structure: Separate Chair (Vikram Malik) and CEO roles to reinforce independent oversight.
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer (director) | $50,000 | Paid quarterly; pro‑rated for 2024 service starting July 1 |
| Committee fee – Compensation Committee (member) | $7,500 | Annualized, paid quarterly; pro‑rated for 2024 |
| 2024 cash fees actually paid | $29,000 | Reflects pro‑rated retainer/committee fees for partial year |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Grant‑Date Fair Value | Vesting |
|---|---|---|---|---|
| RSUs (initial director grant) | Jul 1, 2024 | 23,014 | $254,995 | 50% on Jul 1, 2025; 50% on Jul 1, 2026, subject to service |
No director performance‑conditioned equity (e.g., PRSUs) disclosed for White; annual director awards at Evolus are primarily time‑based RSUs and options (White’s initial grant was RSUs only).
Other Directorships & Interlocks
- Current public company board: The Cooper Companies, Inc. (COO). No disclosed interlocks or related‑party transactions with Evolus.
- Compensation Committee interlocks: None; the proxy reports no interlocks or insider participation conflicts for the compensation committee.
Expertise & Qualifications
- Strategic and operating leadership of a global medtech company (CEO; prior CFO/strategy roles) .
- Capital markets, investor relations, and treasury expertise from senior finance roles .
- Independence and governance familiarity; experience suitable for compensation oversight.
Equity Ownership
| Holder | Beneficial Ownership (shares) | % of Outstanding | Breakdown/Notes |
|---|---|---|---|
| Albert White III | 2,786 | <1% | Includes options to purchase 2,786 shares exercisable within 60 days of Apr 18, 2025 |
| Unvested RSUs (not counted as beneficial) | 23,014 | — | RSUs granted Jul 1, 2024; unvested at Dec 31, 2024 |
- Hedging/pledging: Prohibited by Evolus Insider Trading Policy; no pledging of shares permitted.
- Clawback: Company maintains an executive compensation recovery policy consistent with SEC/Nasdaq rules.
Governance Assessment
- Board effectiveness: White adds seasoned public‑company CEO and prior CFO/strategy expertise to compensation oversight; independence confirmed by the board. His assignment to the Compensation Committee aligns with his background.
- Alignment and incentives: Director pay mix is primarily equity (time‑based RSUs) plus modest cash retainers/committee fees; initial RSU grant vests over two years, encouraging medium‑term alignment without short‑term performance gaming. 2024 actual director pay for White was $284,000, with $255,000 in equity and $29,000 in cash.
- Conflicts and related‑party exposure: Company disclosed no related‑party transactions involving White; independence and no interlock concerns noted. Pledging/hedging barred; robust clawback policy reduces compensation risk.
- Engagement: Attendance standards met across the board; board and compensation committee maintained regular cadence (six compensation committee meetings in 2024).
- Shareholder signals: Say‑on‑pay support at ~91% in 2024 indicates constructive shareholder sentiment toward Evolus’ compensation practices; while focused on executives, it reflects broader governance credibility.
Potential RED FLAGS: None specific to White disclosed. Monitoring items include dual‑hat role as CEO/director at COO (industry adjacency rather than direct competitive overlap) and ensuring ongoing independence and time availability; current filings do not indicate conflicts.